Week in Review: Hua Medicine Approved for $200 Million Hong Kong IPO

Deals and Financings Hua Medicine of Beijing will stage a Hong Kong IPO (rumored at $200 million) to support its novel diabetes treatment that is on track for a 2020 launch; China Resources Pharma will pay $667 million to acquire all the outstanding shares of Jiangzhong Pharma, which will follow its $613 million acquisition of a majority share of Jiangzhong Group, the parent; Suzhou 's CStone Pharma signed a $386 million deal for China rights to three oncology candidates from Blueprint Medicines of Cambridge, Mass.; Quantum Surgical of France received an investment from Ally Bridge as a part of a $50 million Series A round for its minimally invasive surgical tools for cancer; Hangzhou Just Biotherapeutics completed a $35 million Series B+ round to develop its global antibody and recombinant protein biologic drug portfolio; Oncologie, a Boston-Shanghai startup, launched with $16.5 million in seed financing to develop drugs that improve the efficacy of immune checkpoint inhibitors; Denovo, a San Diego-Beijing precision medicine company, announced a license with Stanford University to develop Denovo's own lead oncology drug for pulmonary hypertension; Harbour BioMed, which has an R&D operation in Shanghai , will collaborate with Wistar Institute to co-discover novel antibodies for cancer and infectious diseases; Company News Xiangxue Pharma will build a cell-therapy production facility in Guangzhou using GE Healthcare's prefabricated FlexFactory™ system; Trials and Approvals Nanjing Frontier Biotech received CFDA approval for its long-acting HIV treatment and the first China-developed treatment for HIV to be approved for commercialization.  Stock Symbols: (HK: 3320) (SHA: 600750) (NSDQ: BPMC) (SHE: 300147) Share this with colleagues: // //